All In Biotech

Drug Trial Radar · NCT05372354

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of CC-92480 (BMS-986348) in Novel Therapeutic Combinations in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 260 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

260

Planned (sponsor's estimate)

Start

Oct 18, 2022

Primary completion

Oct 12, 2026

Study completion Oct 12, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
May 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • CC-92480Drug

    Specified dose on specified days

  • TazemetostatDrug

    Specified dose on specified days

  • BMS-986158Drug

    Specified dose on specified days

  • TrametinibDrug

    Specified dose on specified days

  • DexamethasoneDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: From first participant first visit until 28 days after the last participant discontinues study treatment, up to approximately 4 years
  2. Number of participants with Serious AEsTime frame: Up to approximately 4 years
  3. Number of participants with AEs meeting protocol-defined DLT criteriaTime frame: Up to approximately 4 years
  4. Number of participants with AEs leading to discontinuationTime frame: Up to approximately 4 years
  5. Number of deathsTime frame: Up to approximately 4 years
  6. Establish recommended Phase 2 dose (RP2D)Time frame: Up to approximately 2 years
  7. Establish dosing schedule of each combination for Part 2 Dose ExpansionTime frame: Up to approximately 2 years

Locations

17 sites in 5 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama · Recruiting

  • Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • John Theurer Cancer Center at Hackensack UMC

    Hackensack, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Alberta Health Services AHS - Foothills Medical Centre FMC

    Calgary, Alberta, Canada · Recruiting

  • University of Alberta - Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • University Health Network UHN - Princess Margaret Hospital PMH

    Toronto, Ontario, Canada · Recruiting

  • Oslo University Hospital

    Oslo, Outside US and Canada, Norway · Recruiting

  • ICO - Hospital Germans Trias i Pujol

    Barcelona, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario Marques de Valdecilla

    Santander, Spain · Recruiting

  • NIHR UCLH Clinical Research Facility

    London, United Kingdom · Recruiting

  • The Christie NHS Foundation Trust

    Manchester, Greater Manchester, United Kingdom · Recruiting

  • Local Institution - 0001

    Leicester, Leicestershire, United Kingdom · Withdrawn

  • Local Institution - 0014

    Liverpool, Merseyside, United Kingdom · Withdrawn

  • Churchill Hospital

    Oxford, Oxfordshire, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.